Abstract 1981
Background
The LURET phase II trial evaluated the efficacy and safety of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC). Among eligible patients included in primary analysis, objective response rate (ORR) met the primary endpoint (53% [90% CI 31-74]). Here, we report a final analysis of survival outcomes in LURET.
Methods
In all, 19 patients with advanced RET-rearranged NSCLC continuously received 300 mg of oral vandetanib daily. The variant types of RET fusion included 10 KIF5B-RET, 6 CCDC6-RET, and 3 unknown. The data cutoff date was Aug 31, 2017, for a final analysis. In this final analysis, the data on progression-free survival (PFS), overall survival (OS) and safety were updated.
Results
At the final data cutoff, 1 patient was still receiving vandetanib without disease progression. Among all 19 patients in the intention-to-treat population, median PFS was 6.5 months (95% CI, 2.8-8.5) as determined by the independent radiology review committee. Median OS was 13.5 months (95% CI, 9.8-28.1) and the overall survival rate at 12 months was 52.6% (95% CI 28.7-71.9). In the subgroup analysis according to the type of RET fusion, median PFS and OS were 2.9 months (95% CI 1.1-15.7) and 10.5 months (95% CI 3.0-18.1) in patients with KIF5B-RET whereas 8.4 (95% CI 4.7-not reached [NR]) and NR (95% CI 9.9-NR) in those with CCDC6-RET. No new adverse events were observed compared with previous studies in unselected NSCLC.
Conclusions
Our results found that vandetanib to be effective in patients with advanced RET-rearranged NSCLC, and that RET rearrangement may be a favorable molecular subgroup of NSCLC suitable for targeted therapy.
Clinical trial identification
This study is registered with UMIN-CTR, number UMIN000010095.
Legal entity responsible for the study
National Cancer Center Hospital East.
Funding
Sanofi, AstraZeneca, the Ministry of Health, Labour, and Welfare of Japan and the Practical Research for Innovation Cancer Control from the Japan Agency for Medical Research and Development, AMED.
Editorial Acknowledgement
Not applicable
Disclosure
K. Yoh, T. Seto, M. Satouchi: Research funding and honoraria: AstraZeneca. M. Nishio, H. Murakami: Speakers’ bureau, Research funding and honoraria: AstraZeneca. N. Nogami: Research honoraria: AstraZeneca. A. Sato: Speakers’ bureau: AstraZeneca. K. Goto: Research funding: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract